Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Innate Pharma (IPHA) has reported Cash & Equivalents for 9 consecutive years, with $32.0 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 57.69% year-over-year to $32.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.0 million (down 57.69% YoY) and the FY2025 annual result came in at $32.0 million, down 57.69% from the prior year.
• Cash & Equivalents eased to $32.0 million in Q4 2025 per IPHA's latest filing, from $61.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IPHA reached as high as $118.3 million in Q2 2021 and fell as low as $32.0 million in Q4 2025.
• A 5-year average of $85.9 million and a median of $80.8 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents tumbled 99.91% — and 2022, when it dropped 0.99%.
• Year by year, Cash & Equivalents stood at $118.1 million in 2021, then dropped by 18.82% to $95.8 million in 2022, then decreased by 16.17% to $80.3 million in 2023, then dropped by 5.96% to $75.6 million in 2024, then plunged by 57.69% to $32.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $32.0 million, $61.1 million, and $75.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.